Similarly, earlier in this article, we have reviewed that STINGVAX (a STING agonist), as the first designed cancer vaccine containing granulocyte-macrophage colony-stimulating factor (GM-CSF) and CDNs, exerted a significant anti-tumor efficacy in multiple therapeutic models via increasing CD8+ TILs infiltration (45). This evidence concerns the gene STING1 and neoplasm.